Although young lung patients had better outcomes and many molecular features of them predicted a good prognosis, however, there were still the EGFR-TKI resistance pathway and BCL2L11 deletion polymorphism, as well as diverse EGFR 20 insertions, which may have an adverse influence on those patients, suggesting that the young group still needs more caution for treatment choice and monitoring after the treatment, and this may further improve the prognosis of young lung cancer patients. The gene discussed is EGFR; the disease is lung carcinoma.